Companies › Shenzhen Majory Biotechnology
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MR001 Bispecific antibody | – | Phase 1 | Pancreatic Ductal Adenocarcinoma (PDAC); Triple-Negative Breast Cancer (TNBC) | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07235202 | MR001 | Phase 1 | Pancreatic Ductal Adenocarcinoma (PDAC) | Oncology | Jun 2028 |
| NCT07208149 | MR001 | Phase 1 | Triple-Negative Breast Cancer (TNBC) | Oncology | Sep 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.